Summary table of different Cox PHM models to compare them
|
|
7
|
588
|
December 23, 2024
|
Interrupted Time Series, estimates before and after jump
|
|
2
|
333
|
November 23, 2024
|
Non Inferiority vs Non significant
|
|
17
|
756
|
December 19, 2024
|
Least damaging way to convert model predictions to scores
|
|
8
|
341
|
November 29, 2024
|
Advice for appropriate causal model and analysis method
|
|
13
|
1208
|
November 19, 2024
|
Overall survival vs disease-free survival and other surrogate endpoints
|
|
6
|
7932
|
November 5, 2024
|
Randomized non-comparative trials: an oxymoron?
|
|
16
|
1596
|
October 15, 2024
|
Interpreting the coefficient of a log transformed dependent variable
|
|
2
|
569
|
September 11, 2024
|
Causal inferences from RCTs- could “toy” clinical examples promote understanding?
|
|
13
|
978
|
September 2, 2024
|
Individual response
|
|
247
|
43429
|
August 21, 2024
|
Use of percentage change in clinical trials
|
|
17
|
6257
|
July 22, 2024
|
Evaluating seizures in open-label studies
|
|
8
|
980
|
July 21, 2024
|
Appropriate to do lasso, then standard glm using variables with non-zero coef. from lasso?
|
|
1
|
541
|
July 2, 2024
|
Estimands from zero-inflated regression model
|
|
9
|
1054
|
June 20, 2024
|
ITT analysis under equally high non-adherence in both arms in RCT
|
|
4
|
706
|
June 9, 2024
|
Can we think of competing-event as another form of non-event in terms of utility?
|
|
0
|
782
|
April 21, 2024
|
Is Lithium Equivalent to Lecanemab in Slowing cognitive decline in Alzheimer's Disease?
|
|
0
|
871
|
February 23, 2024
|
Review of Trial at the Center of the Firestorm Over Early Connection of Patients to Ventilators during the Pandemic
|
|
34
|
4631
|
February 16, 2024
|
Does subtracting/or not, the mean-rank in Wilcoxon-Mann-Whitney make any difference?
|
|
4
|
978
|
February 1, 2024
|
Ranked analysis of ANCOVA
|
|
7
|
2366
|
January 21, 2024
|
AUC of each subgroup is smaller than overall AUC
|
|
7
|
5071
|
November 13, 2023
|
Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times
|
|
2
|
1172
|
October 3, 2023
|
About the interpret category
|
|
1
|
3277
|
October 3, 2023
|
Comparing "all active dose" to placebo - do we treat "all active dose" as one group or separate groups?
|
|
2
|
976
|
September 4, 2023
|
Guidance of analysis of longitudinal patient reported outcomes w.r.t Joint models
|
|
4
|
1355
|
August 29, 2023
|
Design of Experiments in Economics vs Medicine: a Decision Theory POV
|
|
6
|
2376
|
July 27, 2023
|
Inferences from summary data - without seeing the data for a Cox PH model, do chi square tests tell us anything?
|
|
5
|
547
|
July 24, 2023
|
Case-control study with and corresponding subgroup
|
|
2
|
897
|
July 20, 2023
|
Impact of Model Intercepts on Ordinal Logistic Regression Outcome
|
|
7
|
2088
|
June 22, 2023
|
P values and small sample size
|
|
6
|
1184
|
June 20, 2023
|